Real-World Treatment Patterns and Survival Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with a Selinexor-Containing Triplet-Based Regimen
Treatment for relapsed/refractory multiple myeloma (RRMM) is complex, with several classes of drugs that can be combined into doublet, triplet, or quadruplet regimens. Real-world studies can help to determine the optimal treatment sequences and dosing through observed usage of drugs outside of clini...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-05-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/32/5/268 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849327639355981824 |
|---|---|
| author | Andrew Whiteley Stephen C. Ijioma David Ray Spencer S. Langerman Ellen Hu Amy Pierre Tomer Mark Habte Yimer |
| author_facet | Andrew Whiteley Stephen C. Ijioma David Ray Spencer S. Langerman Ellen Hu Amy Pierre Tomer Mark Habte Yimer |
| author_sort | Andrew Whiteley |
| collection | DOAJ |
| description | Treatment for relapsed/refractory multiple myeloma (RRMM) is complex, with several classes of drugs that can be combined into doublet, triplet, or quadruplet regimens. Real-world studies can help to determine the optimal treatment sequences and dosing through observed usage of drugs outside of clinical trials. Previous clinical trials have demonstrated high rates of durable responses in the treatment of patients with triple-class-exposed RRMM with regimens containing selinexor, a first-in-class, orally available selective exportin 1 inhibitor. This study analyzed real-world treatment patterns and survival outcomes using a nationwide electronic health record-derived, deidentified database of patients with RRMM treated with an eligible selinexor-containing, triplet-based regimen, including combinations with dexamethasone and pomalidomide, bortezomib, carfilzomib, or daratumumab. Patients had a real-world overall survival (rwOS) of 14.7 months (95% CI: 10.6, 20.9) and a derived progression-free survival (dPFS) of 4.7 months (95% CI: 3.4, 6.7). Patients with previous exposure to anti-CD38 monoclonal antibodies (mAbs) in the most recent regimen prior to the selinexor treatment had numerically higher survival outcomes (rwOS, 20.9; dPFS, 8.7 months). These data suggest that, in the real-world setting, the use of selinexor triplet regimens is effective in patients with RRMM, especially those with prior exposure to an anti-CD38 mAb in the immediate prior line of therapy. |
| format | Article |
| id | doaj-art-4c13a9df096947bb82c88dd38cbd46c4 |
| institution | Kabale University |
| issn | 1198-0052 1718-7729 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj-art-4c13a9df096947bb82c88dd38cbd46c42025-08-20T03:47:49ZengMDPI AGCurrent Oncology1198-00521718-77292025-05-0132526810.3390/curroncol32050268Real-World Treatment Patterns and Survival Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with a Selinexor-Containing Triplet-Based RegimenAndrew Whiteley0Stephen C. Ijioma1David Ray2Spencer S. Langerman3Ellen Hu4Amy Pierre5Tomer Mark6Habte Yimer7Texas Oncology-Baylor Sammons Cancer Center, 3410 Worth Street, Suite 400, Dallas, TX 75246, USAKaryopharm Therapeutics, Newton, MA 02459, USAKaryopharm Therapeutics, Newton, MA 02459, USAFlatiron Health, Inc., New York, NY 10013, USAFlatiron Health, Inc., New York, NY 10013, USAFlatiron Health, Inc., New York, NY 10013, USAKaryopharm Therapeutics, Newton, MA 02459, USATexas Oncology-Tyler, Tyler, TX 75702, USATreatment for relapsed/refractory multiple myeloma (RRMM) is complex, with several classes of drugs that can be combined into doublet, triplet, or quadruplet regimens. Real-world studies can help to determine the optimal treatment sequences and dosing through observed usage of drugs outside of clinical trials. Previous clinical trials have demonstrated high rates of durable responses in the treatment of patients with triple-class-exposed RRMM with regimens containing selinexor, a first-in-class, orally available selective exportin 1 inhibitor. This study analyzed real-world treatment patterns and survival outcomes using a nationwide electronic health record-derived, deidentified database of patients with RRMM treated with an eligible selinexor-containing, triplet-based regimen, including combinations with dexamethasone and pomalidomide, bortezomib, carfilzomib, or daratumumab. Patients had a real-world overall survival (rwOS) of 14.7 months (95% CI: 10.6, 20.9) and a derived progression-free survival (dPFS) of 4.7 months (95% CI: 3.4, 6.7). Patients with previous exposure to anti-CD38 monoclonal antibodies (mAbs) in the most recent regimen prior to the selinexor treatment had numerically higher survival outcomes (rwOS, 20.9; dPFS, 8.7 months). These data suggest that, in the real-world setting, the use of selinexor triplet regimens is effective in patients with RRMM, especially those with prior exposure to an anti-CD38 mAb in the immediate prior line of therapy.https://www.mdpi.com/1718-7729/32/5/268real-world studyrelapsed/refractory multiple myelomaselinexor |
| spellingShingle | Andrew Whiteley Stephen C. Ijioma David Ray Spencer S. Langerman Ellen Hu Amy Pierre Tomer Mark Habte Yimer Real-World Treatment Patterns and Survival Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with a Selinexor-Containing Triplet-Based Regimen Current Oncology real-world study relapsed/refractory multiple myeloma selinexor |
| title | Real-World Treatment Patterns and Survival Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with a Selinexor-Containing Triplet-Based Regimen |
| title_full | Real-World Treatment Patterns and Survival Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with a Selinexor-Containing Triplet-Based Regimen |
| title_fullStr | Real-World Treatment Patterns and Survival Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with a Selinexor-Containing Triplet-Based Regimen |
| title_full_unstemmed | Real-World Treatment Patterns and Survival Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with a Selinexor-Containing Triplet-Based Regimen |
| title_short | Real-World Treatment Patterns and Survival Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with a Selinexor-Containing Triplet-Based Regimen |
| title_sort | real world treatment patterns and survival outcomes of patients with relapsed refractory multiple myeloma treated with a selinexor containing triplet based regimen |
| topic | real-world study relapsed/refractory multiple myeloma selinexor |
| url | https://www.mdpi.com/1718-7729/32/5/268 |
| work_keys_str_mv | AT andrewwhiteley realworldtreatmentpatternsandsurvivaloutcomesofpatientswithrelapsedrefractorymultiplemyelomatreatedwithaselinexorcontainingtripletbasedregimen AT stephencijioma realworldtreatmentpatternsandsurvivaloutcomesofpatientswithrelapsedrefractorymultiplemyelomatreatedwithaselinexorcontainingtripletbasedregimen AT davidray realworldtreatmentpatternsandsurvivaloutcomesofpatientswithrelapsedrefractorymultiplemyelomatreatedwithaselinexorcontainingtripletbasedregimen AT spencerslangerman realworldtreatmentpatternsandsurvivaloutcomesofpatientswithrelapsedrefractorymultiplemyelomatreatedwithaselinexorcontainingtripletbasedregimen AT ellenhu realworldtreatmentpatternsandsurvivaloutcomesofpatientswithrelapsedrefractorymultiplemyelomatreatedwithaselinexorcontainingtripletbasedregimen AT amypierre realworldtreatmentpatternsandsurvivaloutcomesofpatientswithrelapsedrefractorymultiplemyelomatreatedwithaselinexorcontainingtripletbasedregimen AT tomermark realworldtreatmentpatternsandsurvivaloutcomesofpatientswithrelapsedrefractorymultiplemyelomatreatedwithaselinexorcontainingtripletbasedregimen AT habteyimer realworldtreatmentpatternsandsurvivaloutcomesofpatientswithrelapsedrefractorymultiplemyelomatreatedwithaselinexorcontainingtripletbasedregimen |